Avita Medical Inc Stock Price, News & Analysis

AVITA Medical announced the first clinical publication of Cohealyx, their collagen-based dermal matrix, in the Journal of Surgery. The study demonstrated significantly faster wound bed vascularization and autograft readiness compared to conventional methods, achieving results in 5-10 days versus the typical 2-4 weeks. In a case series at Ohio State University Wexner Medical Center, two patients with complex hand wounds showed excellent outcomes, with one patient achieving vascularization by day 5 and autografting by day 7, while the second patient reached vascularization by day 10 and autografting by day 13. Cohealyx, developed using proprietary TetraPure Technology, contains crosslinked collagen types I and III, supporting optimal cellular migration and rapid revascularization. The accelerated timeline could improve clinical outcomes by enabling earlier wound closure and reducing patient complications.

AVITA Medical's RECELL platform, including RECELL GO, has won the 'Best New Technology Solution – Surgical' award at the 2025 MedTech Breakthrough Awards. The FDA-approved RECELL technology, used for treating thermal burn wounds and full-thickness skin defects, has successfully treated over 30,000 patients worldwide. The platform's key advantages include requiring less donor skin than traditional grafting, reducing donor-site pain, and accelerating recovery. RECELL GO enhances procedural consistency and surgical team coordination while maintaining physician centrality. The technology has demonstrated improved outcomes including fewer procedures, better functional and aesthetic results, and reduced hospital stays. The recognition came among 4,500 global nominations, with AVITA's SVP Dr. Katie Bush also receiving the 2025 Emerald Pinnacle Healthcare Award in the Medical Device category.

AVITA Medical (NASDAQ: RCEL) is hosting its virtual Acute Wound Care Showcase 2025 on May 13, 2025, at 11:00 a.m. Pacific Time. The event will feature presentations from leading burn and trauma clinicians using AVITA's technologies, alongside patient testimonials about their treatment experiences with the company's solutions.

CEO Jim Corbett and SVP of Scientific and Medical Affairs Dr. Katie Bush will present AVITA's integrated approach to acute wound care, highlighting key technologies including RECELL®, Cohealyx™, and PermeaDerm®. The showcase will include a live Q&A session, with registration available through the company's website. A replay will be accessible from May 14 on AVITA Medical's Investor Relations site.

AVITA Medical (NASDAQ: RCEL) reported strong Q1 2025 financial results with commercial revenue of $18.5 million, up 67% year-over-year, and a robust gross profit margin of 84.7%. The company launched two key products: RECELL GO mini™ in February for smaller wounds, and Cohealyx™ in April, expanding their U.S. market opportunity from $455 million to over $3.5 billion. AVITA has completed its commercial transformation from a single-product burn company to a multi-product platform. The company reaffirmed its 2025 guidance, expecting commercial revenue between $100-106 million (55-65% growth), with anticipated free cash flow in H2 2025 and GAAP profitability in Q4. Despite progress, the company reported a net loss of $13.9 million ($0.53 per share), though improved from $18.7 million loss in Q1 2024.

AVITA Medical (NASDAQ: RCEL) has announced its inaugural Acute Wound Care Showcase 2025, scheduled for May 13, 2025, at 11:00 a.m. Pacific Time via webcast. The event will feature presentations from CEO Jim Corbett and Dr. Katie Bush, Senior Vice President of Scientific and Medical Affairs.

The showcase will highlight AVITA Medical's comprehensive approach to acute wound care, featuring their product portfolio including RECELL®, Cohealyx™, and PermeaDerm®. Attendees will gain insights through physician testimonials and, for the first time, hear directly from patients whose lives have been transformed by these technologies.

The event will demonstrate the clinical and economic benefits of AVITA's technologies and conclude with a live Q&A session. Interested parties can register through the Events & Presentations section of AVITA Medical's Investor Relations website, with a replay available the following day.

AVITA Medical (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound company, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after U.S. market close. The company will host a conference call and webcast on the same day at 1:30 p.m. Pacific Time (May 9, 2025, 6:30 a.m. Australian Eastern Standard Time) to discuss financial performance and recent business highlights.

Investors can access the live webcast through the Events & Presentations section on AVITA Medical's website at ir.avitamedical.com. For telephone participation, advance registration is required to receive dial-in details and a personal PIN.

AVITA Medical (NASDAQ: RCEL) announced the presentation of 16 abstracts at the American Burn Association (ABA) 2025 Annual Meeting in Phoenix, showcasing data across their wound care portfolio including RECELL®, Cohealyx™, and PermeaDerm®.

Key findings include:

• Pre-clinical study on Cohealyx showing support for wound bed vascularization within 7 days
• Largest real-world analysis of over 6,000 RECELL-treated patients demonstrating increasing adoption and consistent clinical utility
• New clinical data on PermeaDerm as an effective temporary wound coverage solution
• Randomized multicenter trial results showing PermeaDerm reduces dressing change frequency and supports early wound healing

The company aims to address the needs of over 450,000 Americans requiring medical treatment for burn injuries annually, focusing on earlier wound closure and reduced procedural complexity.

AVITA Medical (NASDAQ: RCEL) has launched Cohealyx™, a collagen-based dermal matrix co-developed with Regenity Biosciences, expanding its therapeutic wound care portfolio. The product is designed to facilitate cellular migration and revascularization for wound bed preparation, with integrated wound bed formation observed as early as 7 days in initial testing.

Cohealyx complements AVITA's existing products - the RECELL® System (FDA-approved for thermal burns and full-thickness skin defects) and PermeaDerm® (a temporary biosynthetic dressing). This integrated approach supports the two-stage standard of care for full-thickness wounds.

The company is currently conducting the Cohealyx I trial, a post-market study evaluating clinical outcomes and wound bed preparation effectiveness. Pre-clinical studies showed faster graft-ready results compared to leading competitors, potentially leading to shorter hospital stays.

AVITA Medical (NASDAQ: RCEL) has announced new strategic agreements with Stedical Scientific for PermeaDerm® Biosynthetic Wound Matrix. The company will now manufacture PermeaDerm at its Ventura, California facility under a new Contract Manufacturing Agreement effective March 17, 2025.

Key changes include:

• AVITA Medical will now retain 60% of average sales price (up from 50%) after deducting manufacturing costs
• Stedical will receive 40% of sales price (down from 50%)
• The agreement includes new performance-based milestones and extended contract terms

PermeaDerm, an FDA-cleared biosynthetic matrix for wound healing, is reimbursable across U.S. inpatient and outpatient settings. It can be used with AVITA's RECELL® devices and Spray-On Skin™ Cells for various wound types.